{"analyses":[{"ciLowerLimit":"0.5063","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.5276","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.6483","paramType":"Odds Ratio (OR)","paramValue":"0.8794","statisticalMethod":"Chi-squared","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"801"},{"groupId":"OG001","value":"245"}]}],"title":"Primary (initiated in cycle1)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"316"},{"groupId":"OG001","value":"85"}]}],"title":"Secondary (initiated in ≥cycle2)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1117"},{"groupId":"OG001","value":"330"}],"units":"Participants"}],"description":"Objective 2: To describe EP2006 primary or secondary prophylaxis patterns for FN over up to 6 cycles of chemotherapy, with or without prior, concurrent, or later radiotherapy or surgery.","groups":[{"description":"Cancer patients with solid tumor treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG000","title":"EP2006: Solid Tumor"},{"description":"Cancer patients with hematological tumor treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG001","title":"EP2006: Hematological Tumor"}],"paramType":"NUMBER","populationDescription":"Evaluable sample by tumor type","reportingStatus":"POSTED","timeFrame":"All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days","title":"Type of EP 2006 Prophylaxis by Tumor Type","type":"PRIMARY","unitOfMeasure":"participants"}